While Congress has a two-week recess in April, there are many priority items on the agenda this month. Less than two weeks after signing the Fiscal Year (FY) 2022 spending package, President Biden released his budget for FY...more
4/4/2022
/ America Competes Act ,
BsUFA ,
Budgets ,
Centers for Disease Control and Prevention (CDC) ,
Department of Energy (DOE) ,
Energy Sector ,
Food and Drug Administration (FDA) ,
GDUFA ,
Government Shutdown ,
Investment Tax Credits ,
Medical Device User Fee Program (MDUFA IV) ,
Mental Health ,
National Institute of Health (NIH) ,
NATO ,
Nominations ,
Oil & Gas ,
PDUFA ,
Public Health Emergency ,
Russia ,
SAMHSA ,
Semiconductors ,
SFC ,
Ukraine
The first day of spring is right around the corner and so are deadlines for congressional appropriations requests. This month, lawmakers are racing against the clock to fund the government and President Biden looks to...more
3/1/2022
/ Asset Freeze ,
Biden Administration ,
Coronavirus/COVID-19 ,
Department of Energy (DOE) ,
Department of Health and Human Services (HHS) ,
Economic Sanctions ,
Environmental Protection Agency (EPA) ,
Federal Budget ,
Infrastructure ,
National Institute of Health (NIH) ,
Nominations ,
Russia ,
SCOTUS ,
SWIFT ,
Ukraine ,
USAID
Foley & Lardner LLP’s Bipartisan Public Policy Team is pleased to share this week’s “Public Policy Health Care Newsletter” in which we compile the latest health care policy news and legislation. Please note that the next...more
7/30/2018
/ Affordable Care Act ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Food and Drug Administration (FDA) ,
GAO ,
Health Insurance ,
Healthcare Reform ,
HELP ,
Legislative Agendas ,
Medicare ,
Medicare Part D ,
MIPS ,
National Institute of Health (NIH) ,
Opioid ,
Prescription Drugs ,
Section 340B ,
Trump Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly* Health Care Newsletter” in which we compile the latest Health care policy news and legislation. *Please note that we...more
6/21/2018
/ Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
Healthcare ,
HELP ,
Hospitals ,
Medicaid ,
Medicare ,
National Institute of Health (NIH) ,
Opioid ,
Pharmaceutical Industry ,
Proposed Legislation ,
Secretary of HHS ,
Senate Finance Committee ,
Substance Abuse ,
Trump Administration
Foley’s Bipartisan Public Policy Team is pleased to share our “Public Policy Health Care Newsletter” in which we compile the latest health care policy news and legislation. *Please note that we publish this newsletter only...more
6/12/2018
/ Affordable Care Act ,
Appropriations Bill ,
Centers for Medicare & Medicaid Services (CMS) ,
Cybersecurity ,
Department of Health and Human Services (HHS) ,
Federal Budget ,
Food and Drug Administration (FDA) ,
GAO ,
HELP ,
Legislative Agendas ,
Legislative Committees ,
Medicare ,
Medicare Part D ,
National Institute of Health (NIH) ,
Opioid ,
Pharmaceutical Industry ,
Prescription Drugs ,
Preventive Health Care ,
Substance Abuse ,
Trump Administration ,
Ways and Means Committee
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our second “Public Policy Weekly* Health Care Newsletter” in which we compile the latest health care policy news and legislation.
Please...more
5/14/2018
/ Affordable Care Act ,
Centers for Medicare & Medicaid Services (CMS) ,
Children's Health Insurance Program (CHIP) ,
DEA ,
Department of Health and Human Services (HHS) ,
Department of Veterans Affairs ,
Drug Pricing ,
Federal Food Drug and Cosmetic Act (FFDCA) ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Health Insurance ,
Health Insurance Portability and Accountability Act (HIPAA) ,
Healthcare ,
Healthcare Reform ,
Legislative Agendas ,
Medicaid ,
Medicare Part C ,
Mental Health ,
National Institute of Health (NIH) ,
Pharmaceutical Industry ,
Prescription Drugs ,
Regulatory Agenda ,
Section 340B ,
Social Security Act ,
Trade Policy ,
Trump Administration